[1]葛文军,宋继荣.紫杉醇联合洛铂在局部晚期宫颈癌患者术前新辅助化疗中的应用[J].医学信息,2020,33(13):106-108.[doi:10.3969/j.issn.1006-1959.2020.13.029]
　GE Wen-jun,SONG Ji-rong.Paclitaxel Combined with Lobaplatin in Neoadjuvant Chemotherapy for Patients with Locally Advanced Cervical Cancer[J].Medical Information,2020,33(13):106-108.[doi:10.3969/j.issn.1006-1959.2020.13.029]
点击复制

紫杉醇联合洛铂在局部晚期宫颈癌患者术前新辅助化疗中的应用()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年13期
页码:
106-108
栏目:
临床研究
出版日期:
2020-07-01

文章信息/Info

Title:
Paclitaxel Combined with Lobaplatin in Neoadjuvant Chemotherapy for Patients with Locally Advanced Cervical Cancer
文章编号:
1006-1959（2020）13-0106-03
作者:
葛文军; 宋继荣
（1.佳木斯大学研究生院，黑龙江 佳木斯 154002；2.鹤岗市妇女儿童医院妇产科，黑龙江 鹤岗 154100；3.佳木斯大学附属第一医院妇产科，黑龙江 佳木斯 154002）
Author(s):
GE Wen-jun; SONG Ji-rong
(1.Graduate School of Jiamusi University,Jiamusi 154002,Heilongjiang,China;2.Department of Obstetrics and Gynecology,Hegang Women and Children Hospital,Hegang 154100,Heilongjiang,China;3.Department of Obstetrics and Gynecology,the First Affiliated Hospi
关键词:
宫颈癌; 紫杉醇; 洛铂; 手术; 化疗
Keywords:
Cervical cancer; Paclitaxel; Lobaplatin; Surgery; Chemotherapy
分类号:
R737.33
DOI:
10.3969/j.issn.1006-1959.2020.13.029
文献标志码:
A
摘要:
目的 研究紫杉醇联合洛铂在局部晚期宫颈癌（LACC）患者术前新辅助化疗中的应用效果。方法 选取2017年6月~2018年12月经我院病理确诊的LACC患者68例，按照随机数字表法分为两组，每组34例。对照组仅单纯采用经腹根治性子宫切除术治疗，观察组在术前予以紫杉醇联合洛铂的新辅助化疗方案治疗。比较两组临床疗效（疾病总缓解率）、治疗前后血清肿瘤标志物水平[血清细胞角蛋白19片段抗原21-1（CY-FRA21-1）、鳞状上皮癌抗原（SCCAg）]、不良反应发生情况、术后淋巴结转移及复发情况。结果 观察组治疗后的CY-FRA21-1、SCCAg水平低于对照组，差异有统计学意义（P＜0.05）；观察组疾病总缓解率高于对照组，差异有统计学意义（P＜0.05）；观察组治疗后淋巴结转移率、复发率均低于对照组，差异有统计学意义（P＜0.05）；观察组化疗毒副反应轻微。结论 对LACC患者采用紫杉醇联合洛铂的术前新辅助化疗方案疗效和安全性较好，有助于降低血清肿瘤标志物水平，减少术后淋巴结转移及复发情况。
Abstract:
Objective To study the effect of paclitaxel combined with Lobaplatin in neoadjuvant chemotherapy for patients with locally advanced cervical cancer (LACC).Methods A total of 68 patients with LACC diagnosed by pathology in our hospital from June 2017 to May 2018 were selected and divided into two groups according to the random number table method, 34 cases in each group. The control group was only treated by radical abdominal hysterectomy, and the observation group was treated with neoadjuvant chemotherapy of paclitaxel combined with Lobaplatin before surgery. Comparison of clinical efficacy (total remission rate of the disease), serum tumor marker levels before and after treatment [serum cytokeratin 19 fragment antigen 21-1 (CY-FRA21-1), squamous cell carcinoma antigen (SCCAg)], adverse reactions occurrence, postoperative lymph node metastasis and recurrence.Results The CY-FRA21-1 and SCCAg levels of the observation group after treatment were lower than the control group, the difference was statistically significant (P＜0.05); the total disease remission rate of the observation group was higher than the control group, the difference was statistically significant (P＜0.05);The lymph node metastasis rate and recurrence rate of the observation group after treatment were lower than that of the control group, the difference was statistically significant (P＜0.05); the side effects of chemotherapy in the observation group were slight.Conclusion The preoperative neoadjuvant chemotherapy of paclitaxel combined with Lobaplatin in LACC patients has good efficacy and safety, which can help to reduce serum tumor marker levels and reduce postoperative lymph node metastasis and recurrence.

参考文献/References:

[1]吴志芬,李爱禄,沈龙德,等.紫杉醇联合洛铂治疗局部晚期子宫颈鳞状细胞癌临床分析[J].当代医学,2019,25(31):100-102.[2]王荣华.术前新辅助化疗治疗局部晚期宫颈癌的临床观察[J].中外医学研究,2019,17(27):26-28.[3]郭蕾,余小青.紫杉醇联合顺铂新辅助化疗治疗局部晚期宫颈癌疗效观察[J].临床合理用药杂志,2019,12(31):91-92.[4]林珍珍.紫杉醇分别联合卡铂、洛铂治疗局部晚期宫颈癌的近期效果、安全性及治疗费用比较[J].中国民康医学,2019,31(12):70-72.[5]李伟芳.紫杉醇与氟尿嘧啶联合顺铂用于局部晚期宫颈癌新辅助化疗效果比较[J].中国民康医学,2019,31(2):59-61.[6]辛佳凌.紫杉醇联合顺铂新辅助化疗在局部晚期宫颈癌中的应用价值分析[J].基层医学论坛,2019,23(22):3235,3240.[7]李娜,熊娇,嫣静,等.紫杉醇联合洛铂治疗局部晚期宫颈癌患者的疗效观察[J].重庆医学,2018,47(12):1635-1638.[8]张印星,潘春燕,陈小刚.紫杉醇联合洛铂新辅助化疗治疗局部晚期宫颈癌的疗效及其对患者血清DcR3及Survivin的影响[J].海南医学,2016,27(18):2948-2951.[9]柯丽娟,孙阳,刘佳华,等.术前应用洛铂联合紫杉醇新辅助化疗方案对局部宫颈癌晚期患者的疗效及预后研究[J].肿瘤药学,2016,6(6):442-445,450.

相似文献/References:

[1]廖加群,曹 雪,陈燕平,等.宫颈癌盆腔淋巴结转移分布及危险因素分析[J].医学信息,2018,31(03):25.[doi:10.3969/j.issn.1006-1959.2018.03.008]
　LIAO Jia-qun,CAO Xue,CHEN Yan-ping,et al.Distribution and Risk Factors of Pelvic Lymph Node Metastasis in Cervical Cancer[J].Medical Information,2018,31(13):25.[doi:10.3969/j.issn.1006-1959.2018.03.008]
[2]徐 洁.宫颈癌筛查及预防的研究进展[J].医学信息,2018,31(09):70.[doi:10.3969/j.issn.1006-1959.2018.09.022]
　XU Jie.Advances in Screening and Prevention of Cervical Cancer[J].Medical Information,2018,31(13):70.[doi:10.3969/j.issn.1006-1959.2018.09.022]
[3]蔡亚磊,邓思雨,杨 健.宫颈癌放疗增敏的研究现状[J].医学信息,2022,35(09):65.[doi:10.3969/j.issn.1006-1959.2022.09.016]
　CAI Ya-lei,DENG Si-yu,YANG Jian.Research Status of Radiotherapy Sensitization for Cervical Cancer[J].Medical Information,2022,35(13):65.[doi:10.3969/j.issn.1006-1959.2022.09.016]
[4]车 莹.HPV感染与宫颈病变相关性的研究[J].医学信息,2022,35(09):84.[doi:10.3969/j.issn.1006-1959.2022.09.021]
　CHE Ying.Study on the Correlation Between HPV Infection and Cervical Lesions[J].Medical Information,2022,35(13):84.[doi:10.3969/j.issn.1006-1959.2022.09.021]
[5]曹 亮,郝 朋,李阳明,等.宫颈癌所致输尿管梗阻患者输尿管支架置入成功率影响因素的Meta分析[J].医学信息,2022,35(09):124.[doi:10.3969/j.issn.1006-1959.2022.09.031]
　CAO Liang,HAO Peng,LI Yang-ming,et al.Meta Analysis of Factors Influencing Success Rate of Ureteral Stent Implantation in Patients with Ureteral Obstruction Caused by Cervical Cancer[J].Medical Information,2022,35(13):124.[doi:10.3969/j.issn.1006-1959.2022.09.031]
[6]覃念群,刘 楷,米镜霖,等.基于生物信息学分析筛选与宫颈癌预后相关的关键基因[J].医学信息,2022,35(10):8.[doi:10.3969/j.issn.1006-1959.2022.10.002]
　QIN Nian-qun,LIU Kai,MI Jing-lin,et al.Screening Key Genes Related to the Prognosis of Cervical Cancer Based on Bioinformatics Analysis[J].Medical Information,2022,35(13):8.[doi:10.3969/j.issn.1006-1959.2022.10.002]
[7]黄 花,徐冬冬,章丽霞.TGF-β1在宫颈癌中的研究进展[J].医学信息,2018,31(12):31.[doi:10.3969/j.issn.1006-1959.2018.12.011]
　HUANG Hua,XU Dong-dong,ZHANG Li-xia.Research Progress of TGF-β1 in Cervical Cancer[J].Medical Information,2018,31(13):31.[doi:10.3969/j.issn.1006-1959.2018.12.011]
[8]夏易曼娜,李虎成.腹腔镜下宫颈癌根治术与传统开腹手术的对比研究[J].医学信息,2018,31(12):115.[doi:10.3969/j.issn.1006-1959.2018.12.036]
　XIA Yi-manna,LI Hu-cheng.Comparative Study of Laparoscopic Radical Resection of Cervical Cancer and Traditional Open Surgery[J].Medical Information,2018,31(13):115.[doi:10.3969/j.issn.1006-1959.2018.12.036]
[9]杨 军,王翠平,李 龙,等.义安区体检HPV-DNA筛查结果分析[J].医学信息,2018,31(14):136.[doi:10.3969/j.issn.1006-1959.2018.14.041]
　YANG Jun,WANG Cui-ping,LI Long,et al.Analysis of the Results of HPV-DNA Screening in the Medical Examination of Yian District[J].Medical Information,2018,31(13):136.[doi:10.3969/j.issn.1006-1959.2018.14.041]
[10]王双英,张 娜,刘 芳.具有高危复发因素的早期宫颈癌术后辅助治疗进展[J].医学信息,2018,31(15):33.[doi:10.3969/j.issn.1006-1959.2018.15.012]
　WANG Shuang-ying,ZHANG Na,LIU Fang.Advances in Postoperative Adjuvant Therapy for Early Cervical Cancer with High Risk of Recurrence[J].Medical Information,2018,31(13):33.[doi:10.3969/j.issn.1006-1959.2018.15.012]

更新日期/Last Update: 1900-01-01